ÂÜÀòÂÒÂ×

Nushmia Khokhar, MD Prior to joining the Company Dr. Khokar was Chief Medical Officer at Umoja Biopharma, where she was responsible for clinical development, operations and regulatory functions. Before that she was the Senior Vice President, Head of Clinical Development at Autolus and played a critical role in advancing the company’s autologous T-cell products and clinical programs. She also held numerous roles of increasing responsibility at Janssen Oncology, leading several successful clinical trials, directing the Phase 3 registration trial of trabectedin (YONDELIS®) in soft tissue sarcomas, and serving as the Global Clinical Leader for the breakthrough therapy daratumumab (DARZALEX®) for hematologic cancers. Dr. Khokhar received her medical training from the Aga Khan University in Pakistan before completing a post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center, with a focus on pharmacology and molecular therapeutics. She completed a residency in internal medicine at Washington Hospital Center in Washington, D.C. prior to completing a Hematology/Oncology Fellowship at the Northwestern University Feinberg School of Medicine.